- Maravai LifeSciences has announced the acquisition of the DNA and RNA business of Officinae Bio, a technology company specializing in mRNA prototyping and sequence design.
- This acquisition will expand Maravai’s nucleic acid production services, enhancing capabilities for innovative therapeutic development.
Maravai LifeSciences, announced it will acquire the DNA and RNA business of Officinae Bio, an Italy-based biotechnology company. This move aims to strengthen Maravai and its subsidiary, Trilink BioTechnologies, in advancing nucleic acid-based therapeutic development.
Officinae Bio, headquartered in Venice, brings proprietary digital technology that supports the biological design of therapeutic candidates. Their platform enables the rapid prototyping of mRNA candidates and allows researchers to explore diverse combinations of CAP analogs, chemistry modifications, and sequence designs. This acquisition is expected to complement Maravai’s capabilities, particularly in nucleic acid production, which is central to developing innovative therapies.
Trey Martin, CEO of Maravai LifeSciences, remarked, “Officinae Bio’s unique approach to sequence design brings a cutting-edge advantage to our Nucleic Acid Production business. Its founder-led, experienced team maintains a dedicated focus on leveraging AI to help scale the organisation and accelerate innovation.”
Officinae Bio’s CEO, Davide De Lucrezia, highlighted that the company’s focus on scientific collaboration and customer success aligns well with Maravai’s mission. De Lucrezia noted that joining forces with Maravai and Trilink BioTechnologies will enhance their contributions to the GMP manufacturing of key enzymes essential in nucleic acid vaccine and therapeutic applications.
Overview of outsourcing trends 
